Genomic Analysis Yields ‘Hypothesis Generating’ Data in Bladder Cancer SubtypeFebruary 26th 2023
An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.
Perspectives on First-Line Treatment Decision-Making for la/mUC: Results of The Targeted Literature Search and Qualitative InterviewsJuly 14th 2022
Experts discuss results from the targeted literature search and qualitative interviews, which identify important factors that impact their treatment decisions for patients with locally advanced/metastatic urothelial carcinoma.
Treatment Options After Progression on Frontline Maintenance TherapyMay 13th 2022
Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.